Instrumentarium's profits fall as marketing expands
This article was originally published in Clinica
In the first eight months of 1995, Instrumentarium's net profits fell to FMk 111 million ($25 million) compared with FMk 153 million in the previous year. The Finnish company attributes the decline to expansion of its global sales network for healthcare equipment as well as additional R&D investment. The acquisition of the Engstrom anaesthesia and critical care businesses in autumn 1994 caused costs to increase more than net sales, says the company. Total turnover rose 6% to FMk 1,322 million.
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.